Related Experiment Videos
Prostate cancer and neuroendocrine differentiation
M O Tan1, U Karaoğlan, B Celik
1Department of Urology, Gazi University, Ankara, Turkey.
International Urology and Nephrology
|July 17, 1999
Summary
Neuroendocrine differentiation in prostate adenocarcinoma did not correlate with Gleason score or pathological stage. Further research is needed to understand its prognostic significance in prostate cancer.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prostate adenocarcinoma is a common malignancy.
- Neuroendocrine differentiation (NED) is observed in some prostate cancers.
- The prognostic value of NED in prostate cancer remains unclear.
Purpose of the Study:
- To investigate the correlation between pathological stage, Gleason score, and NED in prostate adenocarcinoma.
- To evaluate the prognostic significance of NED in prostate cancer.
Main Methods:
- Retrospective study of 41 prostate adenocarcinoma patients.
- Immunohistochemical staining for neuron-specific enolase and chromogranin A to determine NED.
- Analysis of correlation with pathological stage and Gleason score.
Main Results:
- NED was present in 53.66% of patients.
- NED incidence was higher in poorly differentiated tumors (Gleason 7-10) but not statistically significant (p=0.09).
- NED was greater in advanced stages (C, D) but not statistically significant (p=0.18).
- Significant correlation found between Gleason score and pathological stage (p=0.002).
- No relationship between NED and 5-year tumor progression (p=0.41).
- Tumor progression increased with higher Gleason score (p=0.02) and pathological stage (p=0.00001).
Conclusions:
- No significant correlation was found between neuroendocrine differentiation and prognostic markers (Gleason score, pathological stage) in prostate adenocarcinoma.
- Gleason score and pathological stage are significant prognostic indicators for tumor progression.